Navigation Links
QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
Date:1/3/2008

lacebo over a 12-week treatment period in women with moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. A total of 826 women were enrolled in the study.

The primary endpoints for the Phase 3 Ophena(TM) clinical trial were defined as the change from baseline to week 12 in the percentage of parabasal cells in the vaginal maturation index, the percentage of superficial cells in the vaginal maturation index, vaginal pH, and the most bothersome moderate to severe vulvovaginal atrophy symptom, consistent with the appropriate FDA guidance. Top-line data indicate that the study achieved a statistically significant result in each of these co-primary endpoints and that Ophena(TM) was well tolerated.

The study investigated two doses of Ophena(TM) versus placebo, administered once daily, with patients randomized (1:1:1) into a double-blind 12-week treatment period with a four-week follow-up or the opportunity to continue in a long-term safety extension study. All subjects were supplied with a non-hormonal vaginal lubricant to be applied as needed during the 12- week treatment period.

Rochelle Hanley, M.D., chief medical officer of QuatRx Pharmaceuticals, added, "Based on this study, we believe Ophena(TM) is the first drug to demonstrate efficacy in this population over and above the use of topical lubricants. These are important new data that underscore the clinical benefit Ophena(TM) could provide for this common chronic condition."

The full data set from the study is currently being analyzed and will be submitted for presentation at an upcoming scientific meeting and for publication in an appropriate peer-reviewed setting.

About Postmenopausal Vaginal Syndrome

Postmenopausal vaginal syndrome (PVS) is a chronic condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia), and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to gr
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Pa. , Sept. 15, 2014 /PRNewswire-iReach/ -- ... -based biotechnology company developing calcium phosphate (CaP)-based nanoparticle ... the company has entered a License Agreement with ... biotechnology company developing immunotherapy products for the treatment ... Under the terms of the agreement, ...
(Date:9/15/2014)... , Sept. 15, 2014  Over 200 ... one roof Saturday to learn, interact and participate ... York City,s first Lupus Trials Fair launched by ... the S.L.E. Lupus Foundation .  Attendees interacted ... institutions -- sharing experiences, ideas and needs and ...
(Date:9/15/2014)... LINCOLNSHIRE, Ill. , Sept. 15, 2014 /PRNewswire/ ... testing equipment and information systems technology, announced today ... (LABSCO).  This agreement is for Sysmex reagents, controls ... Sysmex pocH-100 i ™ , Sysmex XP-300™, ... The agreement is effective immediately and continues ...
Breaking Medicine Technology:CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3
... May 9, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... abstracts at the 2011 Digestive Disease Week (DDW) conference ... of DIFICID™ (fidaxomicin), an investigational product for the treatment ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) The first analysis ...
... Australia and BEIJING, May 9, 2011 Saladax Biomedical, ... diagnostic assays to achieve the promise of personalized medicine ... of its Pacific Rim commercialization team to expand its ... Saladax,s Pacific Rim commercialization team include: ...
Cached Medicine Technology:Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 2Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 3Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data 4Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China 2
(Date:9/15/2014)... September 15, 2014 The Best ... World Report consists of seven hospitals using OnBase as ... Hospital and Cleveland Clinic were ranked at the top ... respectively. The rankings cover nearly 5,000 medical centers across ... 17 hospitals that scored highest in at least six ...
(Date:9/15/2014)... 2014 (HealthDay News) -- U.S. heart experts recommend doctors ... when evaluating young people for underlying heart disease that ... Heart Association and the American College of Cardiology said ... and family medical history along with a physical examination ... (existing from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... estimated 8% of Americans will suffer from post traumatic ... Brought on by an overwhelming or stressful event or ... physiology of the brain. Understanding how threat is processed ... is essential to developing effective interventions. , New ... of Texas at Dallas published online today in ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 This year, ... its founding in 2007. To mark the special occasion, ... for supporting the village and helping it to get ... safe, secure and fun community for seniors. Members of ... community and live in their own homes. They are ...
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. 15, 2014 ... responsible for sending thousands of young children to the hospital ... year between 2007 and 2011, about 9,500 U.S. children younger ... family members, medication, according to the U.S. Centers for Disease ... just 1 or 2 years old," said Dr. Daniel Budnitz, ...
Breaking Medicine News(10 mins):Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:EEG study findings reveal how fear is processed in the brain 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 2Health News:Small Number of Drugs Behind Kids' Accidental Poisonings: CDC 3
... Axel Ullrich, Ph.D., is the recipient of the ... his pioneering work in the translation of genomics-based discoveries ... Director of Molecular Biology at the Max Planck Institute ... expert in gene technology and one of the most ...
... of activity helped men, women regardless of family history ... level of aerobic fitness can significantly reduce stroke risk ... study. , The study, expected to be presented Thursday ... New Orleans, showed 30 minutes or more of brisk ...
... connection, experts say , , THURSDAY, Feb. 21 (HealthDay News) ... anywhere else for that matter, may raise your risk ... , "These authors report a potentially important association between ... said Dr. Steven V. Pacia, director of neurology at ...
... similarities, differences in DNA, studies find , , THURSDAY, ... such examination of human genetic diversity yet conducted, an ... to track differences and similarities between people around the ... Science , a team led by Richard Myers, ...
... drugs raises risk of adverse side effects ... take more than one nonsteroidal anti-inflammatory drug (NSAID) may ... suggests. , NSAIDs, which are available in both prescription ... arthritis. , These drugs are widely available, and patients ...
... release is available in Spanish . , ... field of health. However, they are vitally important for patients ... carried out at the Department of Social Anthropology ... lecturer Rafael Briones Gmez, shows that Spanish hospitals are not ...
Cached Medicine News:Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 2Health News:Pezcoller Foundation-AACR International Award for Cancer Research recognizes Axel Ullrich 3Health News:Moderate Aerobic Fitness Levels May Cut Stroke Risk 2Health News:Daytime Dozing Might Raise Stroke Risk 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 2Health News:Global Analysis of Human DNA Tracks Migration, Identity 3Health News:Global Analysis of Human DNA Tracks Migration, Identity 4Health News:Taking Multiple Pain Relievers May Cause Complications 2Health News:Patients' relatives are ignored by the health system and suffer emotional stress 2
... SF (slot format) microfiltration units provide a ... acid in solution onto nitrocellulose or Zeta-Probe ... by using interchangeable templates to form the ... Bio-Dot SF apparatus. Each is available as ...
Dot Blotter - 96-Well Dot Blot...
... base with vacuum stage, porous vacuum plate, reservoir ... instructions. The Model 785 vacuum blotter quickly ... agarose gel onto a nylon membrane. Because it ... nucleic acid samples can be separated on a ...
Mini Trans-Blot and PowerPac 300 System, 110-120 V...
Medicine Products: